Company profile
Endexx Corporation
OTC: EDXC · Healthcare · Drug Manufacturers - Specialty & Generic
#785 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 8GM —SS 43
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), listing tenure · ↓ disclosure history, filing timeliness
Methodology →Revenue TTM
-$987.7k
Rev growth YoY (TTM)
-125.6%
Net income (FY)
-$4.9M
Employees
10
as of 2026-08-28
Market cap
$57.2k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2022
Net income-$4.9M-$4.9M2022
Operating income-$3.9M-$3.9M2022
Total assets$13.3M$13.3M2022
Liabilities$23.0M$23.0M2022
Equity-$11.4M-$11.4M2022
Revenue trend
FY2021 – FY2022 · USD
FY21
FY21
FY22
Revenue by segment
Filed disclosures · FY2021
By product
Wholesale70%
Retail30%
By geography
Not disclosed.
The read
What is Endexx Corporation’s revenue?
Endexx Corporation booked $2.1M in FY2022 revenue, growing 229% year over year — faster than 90% of Healthcare companies we track, at a -228.5% net margin.
Peers · Healthcare
Horizon Space Acquisition II Corp.——Aligos Therapeutics, Inc.47DAmerican Mobile Dental Corp.——BNB Plus Corp.33DGeneLink, Inc.——Aeolus Pharmaceuticals, Inc.——Neighbors
Maricopa →Key facts
CEOBrad Listermann
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCave Creek, AZ
ExchangeOTC: EDXC
Employees10
IPO date2001-08-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.